» Articles » PMID: 33410232

Mediators of Cerebral Hypoperfusion and Blood-brain Barrier Leakiness in Alzheimer's Disease, Vascular Dementia and Mixed Dementia

Overview
Journal Brain Pathol
Date 2021 Jan 7
PMID 33410232
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

In vascular dementia (VaD) and Alzheimer's disease (AD), cerebral hypoperfusion and blood-brain barrier (BBB) leakiness contribute to brain damage. In this study, we have measured biochemical markers and mediators of cerebral hypoperfusion and BBB in the frontal (BA6) and parietal (BA7) cortex and underlying white matter, to investigate the pathophysiology of vascular dysfunction in AD, VaD and mixed dementia. The ratio of myelin-associated glycoprotein to proteolipid protein-1 (MAG:PLP1), a post-mortem biochemical indicator of the adequacy of ante-mortem cerebral perfusion; the concentration of fibrinogen adjusted for haemoglobin level, a marker of blood-brain barrier (BBB) leakiness; the level of vascular endothelial growth factor-A (VEGF), a marker of tissue hypoxia; and endothelin-1 (EDN1), a potent vasoconstrictor, were measured by ELISA in the frontal and parietal cortex and underlying white matter in 94 AD, 20 VaD, 33 mixed dementia cases and 58 age-matched controls. All cases were assessed neuropathologically for small vessel disease (SVD), cerebral amyloid angiopathy (CAA) severity, Aβ and phospho-tau parenchymal load, and Braak tangle stage. Aβ40 and Aβ42 were measured by ELISA in guanidine-HCl tissue extracts. We found biochemical evidence of cerebral hypoperfusion in AD, VaD and mixed dementia to be associated with SVD, Aβ level, plaque load, EDN1 level and Braak tangle stage, and to be most widespread in mixed dementia. There was evidence of BBB leakiness in AD-limited to the cerebral cortex and related to EDN1 level. In conclusion, abnormalities of cerebral perfusion and BBB function in common types of dementia can largely be explained by a combination of arteriolosclerosis, and Aβ-, tau- and endothelin-related vascular dysfunction. The relative contributions of these processes vary considerably both between and within the diseases.

Citing Articles

Cerebral hypoperfusion reduces tau accumulation.

Gheni G, Shinohara M, Masuda-Suzukake M, Shindo A, Watanabe A, Kawai K Ann Clin Transl Neurol. 2024; 12(1):69-85.

PMID: 39621511 PMC: 11752094. DOI: 10.1002/acn3.52247.


Combination treatment with cilostazol and isosorbide mononitrate attenuates microemboli-mediated vascular cognitive impairment and improves imaging and plasma biomarkers in diabetic rats.

Li W, Li A, Nie X, Voltin J, He L, Karakaya E Exp Neurol. 2024; 383:115030.

PMID: 39490626 PMC: 11629300. DOI: 10.1016/j.expneurol.2024.115030.


A systematic review and meta-analysis on the transcriptomic signatures in alcohol use disorder.

Friske M, Torrico E, Haas M, Borruto A, Giannone F, Hade A Mol Psychiatry. 2024; 30(1):310-326.

PMID: 39242950 PMC: 11649567. DOI: 10.1038/s41380-024-02719-x.


Efficacy, safety, and response predictors of Astragalus in patients with mild to moderate Alzheimer's disease: A study protocol of an assessor-blind, statistician-blind open-label randomized controlled trial.

Cheng Y, Lin L, Huang P, Zhang J, Pan X Contemp Clin Trials Commun. 2024; 41:101339.

PMID: 39176240 PMC: 11339046. DOI: 10.1016/j.conctc.2024.101339.


Visualization of Blood-Brain Barrier Disruption in Septic Mice with the New Method Based on in Vivo Imaging Technology.

Zhang H, Ai Y, Zhang X, Deng F, Jiang S, Xie S Neurocrit Care. 2024; 41(3):925-941.

PMID: 38982003 DOI: 10.1007/s12028-024-02018-x.


References
1.
Miners J, Jones R, Love S . Differential changes in Aβ42 and Aβ40 with age. J Alzheimers Dis. 2014; 40(3):727-35. DOI: 10.3233/JAD-132339. View

2.
Nortley R, Korte N, Izquierdo P, Hirunpattarasilp C, Mishra A, Jaunmuktane Z . Amyloid β oligomers constrict human capillaries in Alzheimer's disease via signaling to pericytes. Science. 2019; 365(6450). PMC: 6658218. DOI: 10.1126/science.aav9518. View

3.
Narushima I, Kita T, Kubo K, Yonetani Y, Momochi C, Yoshikawa I . Highly enhanced permeability of blood-brain barrier induced by repeated administration of endothelin-1 in dogs and rats. Pharmacol Toxicol. 2003; 92(1):21-6. DOI: 10.1034/j.1600-0773.2003.920104.x. View

4.
Hartz A, Bauer B, Soldner E, Wolf A, Boy S, Backhaus R . Amyloid-β contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy. Stroke. 2011; 43(2):514-23. PMC: 5761312. DOI: 10.1161/STROKEAHA.111.627562. View

5.
Ellis R, Olichney J, Thal L, Mirra S, Morris J, Beekly D . Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology. 1996; 46(6):1592-6. DOI: 10.1212/wnl.46.6.1592. View